Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Mantle-Cell 26Lymphoma, Non-Hodgkin 22Lymphoma 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, B-Cell 14Lymphoma, Follicular 13Recurrence 12Waldenstrom Macroglobulinemia 9Neoplasms 8Lymphoma, B-Cell, Marginal Zone 6Leukemia, Lymphoid 6Leukemia, B-Cell 6Bronchiolitis Obliterans Syndrome 6Multiple Myeloma 5Graft vs Host Disease 4Lymphoproliferative Disorders 3Lymphatic Diseases 3Leukemia, Myeloid, Acute 3Leukemia 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Neoplasms 3Hematologic Diseases 2Burkitt Lymphoma 2Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1

Interventions

immunotoxin HA22 3Cyclophosphamide 2trametinib 1polatuzumab vedotin 1pembrolizumab 1ontuxizumab 1ibrutinib 1fludarabine 1dabrafenib 1brexucabtagene autoleucel 1acalabrutinib 1Trazodone 1Rituximab 1Prednisone 1PLX8394 1Lenalidomide 1HA 22 1Fentanyl 1Doxorubicin 1AGS67E 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Hairy Cell × ibrutinib × Clear all
NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡